Lanxess (LXS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
19 Mar, 2026Executive summary
Full-year 2025 EBITDA pre exceptionals reached €510 million, down 17% year-over-year, in line with guidance, as Q4 earnings declined sharply due to lower volumes, adverse FX, and the sale of the Urethane Systems business.
Revenue declined 10.9% to €5.673 billion in 2025 amid weak demand and geopolitical uncertainty.
Net financial debt reduced to €2.023 billion by year-end, supported by disciplined working capital management and proceeds from the Urethane Systems sale.
The company exited polymer businesses, focusing on core segments, and initiated permanent cost reductions of €100 million, including 550 job cuts by 2028.
A stable dividend of €0.10 per share is proposed for 2025, maintaining focus on deleveraging.
Financial highlights
Q4 2025 sales were €1,268 million (-14% yoy), with EBITDA pre at €102 million (-36% yoy) and margin at 8.0%.
FY 2025 sales reached €5,673 million (-11% yoy), EBITDA pre exceptionals at €510 million (-16.9% yoy), and margin at 9.0%.
Net income for FY 2025 was -€577 million, impacted by €341 million in impairments.
Free cash flow for FY 2025 was -€30 million, reflecting lower operating results and higher D&A.
Equity ratio remains strong at 45% despite a decrease in total assets and equity.
Outlook and guidance
2026 EBITDA pre exceptionals guidance is set at €450–550 million, reflecting high market volatility and macroeconomic uncertainties.
Cost savings of €150 million targeted by end of 2028, with €100 million by end of 2025.
Business recovery is anticipated no earlier than the second half of 2026, with some positive impulses expected from infrastructure stimulus.
Construction sector recovery is expected earliest in H2 2026; cautious outlook for agro demand.
Free cash flow for 2026 is possible within the guidance range, excluding working capital swings.
Latest events from Lanxess
- Sales and EBITDA fell in 2025, debt reduced, and recovery expected in late 2026 amid cost cuts.LXS
Q4 2025 (Media)19 Mar 2026 - Earnings rose, costs fell, and sustainability advanced amid global uncertainty and strategic refocus.LXS
AGM 20253 Feb 2026 - Q2 2024 EBITDA pre exceptionals surged 69% year-over-year despite lower sales.LXS
Q2 20241 Feb 2026 - EBITDA pre exceptionals jumped 45% and net income returned to profit in Q3 2024.LXS
Q3 202416 Jan 2026 - EBITDA rose 20% in 2024 as cost savings and portfolio focus drove profitability gains.LXS
Q4 202426 Dec 2025 - Q2 sales and EBITDA fell on weak demand, but net debt dropped after Urethane divestment.LXS
Q2 202523 Nov 2025 - EBITDA pre up 32% to €133m; guidance held as Urethane sale supports debt reduction.LXS
Q1 202517 Nov 2025 - EBITDA pre exceptionals rose 32% in Q1 2025, with guidance confirmed at €600–650 million.LXS
Q1 2025(Media)17 Nov 2025 - Sales and EBITDA fell sharply in Q3 2025, with cost cuts and divestments improving leverage.LXS
Q3 20256 Nov 2025